Premenopausal cases | ||||
Tumor characteristic | Minimal/mild BPE | Moderate/marked BPEa | ORb | 95% CI |
Hormone receptor statusc | ||||
 Negative | 48 (15%) | 33 (16%) | Reference |  |
 Positive | 277 (85%) | 178 (84%) | 1.00 | 0.59–1.68 |
HER2 | ||||
 Negative | 277 (85%) | 164 (78%) | Reference |  |
 Positive | 48 (15%) | 47 (22%) | 1.72 | 1.07–2.76 |
Histology | ||||
 Ductal | 293 (90%) | 194 (92%) | Reference |  |
 Lobular/mixed/other | 32 (10%) | 17 (8%) | 0.99 | 0.52–1.91 |
Stage | ||||
 Localized | 220 (68%) | 147 (70%) | Reference |  |
 Regional | 101 (31%) | 60 (28%) | 0.86 | 0.57–1.29 |
 Distant | 4 (1%) | 4 (2%) | 1.45 | 0.34–6.21 |
Postmenopausal cases | ||||
Tumor characteristic | Minimal BPE | Mild/moderate/marked BPE | ORb | 95% CI |
Hormone receptor status | ||||
 Negative | 26 (27%) | 30 (17%) | Reference |  |
 Positivec | 71 (73%) | 145 (83%) | 2.55 | 1.22–5.34 |
Human epidermal growth factor 2 | ||||
 Negative | 83 (86%) | 152 (87%) | Reference |  |
 Positive | 14 (14%) | 23 (13%) | 0.89 | 0.37–2.13 |
Histology | ||||
 Ductal | 80 (82%) | 151 (86%) | Reference |  |
 Lobular/mixed/other | 17 (18%) | 24 (14%) | 0.65 | 0.30–1.43 |
Stage | ||||
 Localized | 76 (78%) | 132 (75%) | Reference |  |
 Regional | 19 (20%) | 41 (23%) | 0.75 | 0.36–1.53 |
 Distant | 2 (2%) | 2 (1%) | 0.36 | 0.04–3.17 |